Tenax Therapeutics Inc - TENX STOCK NEWS

Tenax Therapeutics (Nasdaq: TENX) has reported its Q1 2024 financial results and provided a corporate update. Key highlights include continuing patient enrollment in the Phase 3 LEVEL study with 24 investigative sites initiated and securing global development and commercial rights for levosimendan for PH-HFpEF treatment. A new US patent was granted, expanding their intellectual property estate. In February 2024, Tenax raised approximately $8 million in a public offering. Financially, the company reported a net loss of $3.8 million for Q1 2024, compared to $1.4 million for the same period in 2023, with cash and equivalents at $12.5 million as of March 31, 2024.

Tenax Therapeutics, Inc. announced a new U.S. patent covering the use of levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) until December 2040. The patent broadens protection for oral, IV, and subcutaneous use of levosimendan, and its active metabolites, also allowing for additional U.S. patent term extension. This patent is the third granted to Tenax since March 2023, protecting the use of levosimendan in treating PH-HFpEF.

Tenax Therapeutics, Inc. announces a scientific round-table discussion on the unmet medical need in pulmonary hypertension due to heart failure with preserved ejection fraction (PH-HFpEF) and the potential role of levosimendan in treating this condition. The company will host a webcast to explore the ongoing Phase 3 LEVEL Study evaluating TNX-103 (oral levosimendan) for PH-HFpEF treatment.

Tenax Therapeutics, Inc. (TENX) announces the enrollment of the first patient in the Phase 3 LEVEL trial for TNX-103 in treating Pulmonary Hypertension from Heart Failure with Preserved Ejection Fraction (PH-HFpEF). The company secures global commercial rights for levosimendan, expands U.S. intellectual property, and hosts a KOL event. Recent corporate highlights include securing rights to oral and subcutaneous levosimendan, closing a public offering, and enrolling patients in the LEVEL study. Financially, Tenax reports $9.8 million in cash, raising $8.0 million in a public offering, with reduced R&D and administrative expenses resulting in a net loss of $7.7 million for 2023.

Tenax Therapeutics, Inc. (Nasdaq: TENX) will participate in the 36th Annual Roth Conference to provide an update on the development of levosimendan, a cardiovascular and pulmonary disease treatment. CEO Chris Giordano will present on March 18, 2024, offering investors insights into the company's progress.

Tenax Therapeutics announces Dr. Sanjiv Shah's presentation on levosimendan for PH-HFpEF at THT 2024 conference in Boston.

Tenax Therapeutics, Inc. secures global rights to levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction, expanding territory from North America to worldwide. The agreement with Orion Corporation includes improved net sales royalty rates, modified milestone provisions, and exclusion of neurological indications from Tenax's right of first negotiation for new levosimendan applications.

Tenax Therapeutics, Inc. announced the pricing of a public offering of 1,600,000 shares of its common stock and warrants to purchase up to 3,200,000 shares at a purchase price of $5.65 per share. The offering is expected to close soon, with the proceeds intended for general corporate purposes and working capital.

Tenax Therapeutics, Inc. has announced the enrollment of the first patient in the Phase 3 LEVEL Study, a trial for the treatment of pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF). The study will involve 152 patients and is expected to produce topline data by the second half of 2025. The company has highlighted the reduced costs and time for the registration of TNX-103 due to the FDA not requiring a long-term cardiovascular outcomes trial, and the extensive patent estate for levosimendan until at least 2040.